Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 11/20 | 0.52 |
| ▸ | KDM1A | O60341 | 9/20 | 0.52 |
| ▸ | MAOA | P21397 | 8/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195755 | 0.90 | KDM1A (0.58) | SLC18A3SIGMAR1MAOBKDM1AMAOA | |
| SCHEMBL15054151 | 0.85 | MAOB (0.52) | SLC18A3SIGMAR1MAOBKDM1AMAOA | |
| SCHEMBL10682798 | 0.82 | KDM1A (0.54) | SLC18A3SIGMAR1MAOBKDM1AMAOA | |
| SCHEMBL458289 | 0.82 | KDM1A (0.58) | MAOBKDM1AMAOACYP2C19CYP2B6 | |
| SCHEMBL458287 | 0.82 | KDM1A (0.58) | MAOBKDM1AMAOACYP2C19CYP2B6 | |
| SCHEMBL10682790 | 0.82 | KDM1A (0.54) | SLC18A3SIGMAR1MAOBKDM1AMAOA | |
| SCHEMBL458288 | 0.82 | KDM1A (0.58) | MAOBKDM1AMAOACYP2C19CYP2B6 | |
| SCHEMBL6438894 | 0.82 | KDM1A (0.54) | SLC18A3SIGMAR1MAOBKDM1AMAOA | |
| SCHEMBL6438889 | 0.82 | KDM1A (0.54) | SLC18A3SIGMAR1MAOBKDM1AMAOA | |
| SCHEMBL8043228 | 0.77 | KDM1A (0.50) | SLC18A3SIGMAR1MAOBKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | claimed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| CN-114867720-B | Heteroaryl derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-4092019-A1 | HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-114867720-A | Heteroaryl derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021143680-A1 | HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | SLC18A3 543/4885SIGMAR1 779/4885MAOB 2852/4885 |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | PTPN11, PTPN1, PTPN7 | SLC18A3 4574/4885SIGMAR1 3502/4885MAOB 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.